Skip to main content

Bruker Closes $1.1B BioSpin Acquisition

NEW YORK (GenomeWeb News) – Bruker BioSciences announced after the close of the market last night that it has completed its acquisition of Bruker BioSpin and has been renamed Bruker Corp.
Roughly 57.5 million shares of new, unregistered Bruker common stock worth around $624.9 million were issued for the stock component of the deal. Combined with the $388 million cash component of the deal, the total value of the acquisition is nearly $100 million more than when Bruker announced its intention to buy BioSpin in early December.
Following completion of the acquisition, Bruker will operate in two segments: the life science and analytical systems segment, and the international advanced superconductor segment.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.